We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Anticancer Drug Delivery System Utilizes Graphene Strip Transporters

By LabMedica International staff writers
Posted on 20 Jan 2015
The ongoing search by cancer researchers for targeted drug delivery systems has generated a novel approach that uses graphene strips to transport simultaneously the anticancer agents TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) and Dox (doxorubicin).

Cancer cells can develop resistance to chemotherapy drugs, but are less likely to develop resistance when multiple drugs are delivered simultaneously. More...
However, different drugs target different parts of the cancer cell. For example, the protein drug TRAIL is most effective against the cell membrane, while Dox is most effective when delivered to the nucleus.

Although in use for more than 40 years as a primary chemotherapy drug, Dox is known to cause serious heart problems. To prevent these, doctors may limit the amount of Dox given to each patient so that the total amount a patient receives over her or his entire lifetime is 550 milligrams per square meter, or less. Furthermore, the necessity to stop treatment to protect the patient from heart disease may diminish the usefulness of Dox in treating cancer. TRAIL is a cytokine that is produced and secreted by most normal tissue cells. It causes apoptosis primarily in tumor cells by binding to certain death receptors. Since the mid-1990s it has been used as the basis for several anticancer drugs, but was not been found to have any significant survival benefit.

Investigators at North Carolina State University (Raleigh, USA) and the University of North Carolina (Chapel Hill, USA) have developed a sequential and site-specific delivery technique that first delivers TRAIL to cancer cell membranes and then penetrates the membrane to deliver Dox to the nucleus. In addition, they reported in the December, 15, 2014, online edition of the journal Advanced Materials that TRAIL actively targets molecules that allow it to bind directly to the surface of cancer cells.

The new approach is based on graphene strips loaded with Dox to which TRAIL has been bound by a chain of amino acids. The strips are able to penetrate to the site of a tumor via leaks in blood vessels caused by the cancer. Once in the proximity of the tumor, receptors on the surface of the cancer cells bind TRAIL. Enzymes on the surface of the cancer cells then dissolve the bonds linking TRAIL to the graphene strip, which allows the cells to absorb the Dox-laden graphene. TRAIL remains on the cell surface, where it triggers the process of apoptosis resulting in the destruction of the tumor.

"These drug-rich graphene strips are introduced into the bloodstream in solution, and then travel through the bloodstream like nanoscale flying carpets," said senior author Dr. Zhen Gu, assistant professor in the joint biomedical engineering program at North Carolina State University and the University of North Carolina. "We have demonstrated that TRAIL itself can be used to attach a drug delivery system to a cancer cell, without using intervening material—which is something we did not know, and because graphene has a large surface area, this technique enhances our ability to apply TRAIL to its target on cancer cell membranes."

Related Links:

North Carolina State University
University of North Carolina



New
Gold Member
Ketosis and DKA Test
D-3-Hydroxybutyrate (Ranbut) Assay
Portable Electronic Pipette
Mini 96
Gold Member
Cardiovascular Risk Test
Metabolic Syndrome Array I & II
New
Gold Member
Automatic CLIA Analyzer
Shine i9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: When assessing the same lung biopsy sample, research shows that only 18% of pathologists will agree on a TCMR diagnosis (Photo courtesy of Thermo Fisher)

Molecular Microscope Diagnostic System Assesses Lung Transplant Rejection

Lung transplant recipients face a significant risk of rejection and often require routine biopsies to monitor graft health, yet assessing the same biopsy sample can be highly inconsistent among pathologists.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.